

No	Subject	Register number
----	---------	-----------------

Minutes of Steering Board meetings.

1	Meeting 18 06 2020 - Agenda	Ares(2020)6521588
2	Meeting 18 06 2020 - Minutes	Ares(2020)6521773
3	Meeting 29 06 2020 - Agenda	Ares(2020)6521822
4	Meeting 29 06 2020 – Minutes	Ares(2020)6521864
5	Meeting 03 07 2020- Agenda	Ares(2020)6521899
6	Meeting 03 07 2020 – Minutes	Ares(2020)6521931
7	Meeting 10 07 2020 – Agenda	Ares(2020)6521951
8	Meeting 10 07 2020 – Minutes	Ares(2020)6521990
9	Meeting 17 07 2020 – Agenda	Ares(2020)6522009
10	Meeting 17 07 2020 – Minutes	Ares(2020)6522057
11	Meeting 24 07 2020 - Agenda	Ares(2020)6522069
12	Meeting 24 07 2020 – Minutes	Ares(2020)6522099
13	Meeting 31 07 2020 – Agenda	Ares(2020)6522121
14	Meeting 31 07 2020 – Minutes	Ares(2020)6522141
15	Meeting 07 08 2020 – Agenda	Ares(2020)6522149
16	Meeting 07 08 2020 – Minutes	Ares(2020)6522199
17	Meeting 13 08 2020 – Agenda	Ares(2020)6552323
18	Meeting 13 08 2020 – Minutes	Ares(2021)1548353
19	Meeting 17 08 2020 – Agenda	Ares(2021)1457279
20	Meeting 17 08 2020 – Minutes	Ares(2020)6522199
21	Meeting 19 08 2020 – Agenda	Ares(2020)6522258
22	Meeting 19 08 2020 – Minutes	Ares(2020)6522276
23	Meeting 21 08 2020 – Agenda	Ares(2020)6522301
24	Meeting 21 08 2020 – Minutes	Ares(2020)6522276
25	Meeting 28 08 2020 – Agenda	Ares(2020)6522316
26	Meeting 28 08 2020 – Minutes	Ares(2020)6522337
27	Meeting 02 09 2020 – Agenda	Ares(2020)6522359
28	Meeting 02 09 2020 – Minutes	Ares(2020)6522369
29	Meeting 04 09 2020 – Agenda	Ares(2020)6522388
30	Meeting 04 09 2020 – Minutes	Ares(2020)6522369
31	Meeting 11 09 2020 – Agenda	Ares(2020)6522396
32	Meeting 11 09 2020 – Minutes	Ares(2020)6522410
33	Meeting 17 09 2020 – Agenda	Ares(2020)6522469
34	Meeting 17 09 2020 – Minutes	Ares(2020)6522474
35	Meeting 18 09 2020 – Agenda	Ares(2020)6522482
36	Meeting 18 09 2020 – Minutes	Ares(2020)6522509
37	Meeting 25 09 2020 – Agenda	Ares(2020)6522520
38	Meeting 25 09 2020 – Minutes	Ares(2020)6522524
39	Meeting 02 10 2020 – Agenda	Ares(2020)6522567
40	Meeting 02 10 2020 – Minutes	Ares(2020)6522593
41	Meeting 06 10 2020 – Agenda	Ares(2020)6522574
42	Meeting 06 10 2020 – Minutes	Ares(2020)6522593
43	Meeting 09 10 2020 – Agenda	Ares(2020)6522618
44	Meeting 09 10 2020 – Minutes	Ares(2020)6522697
45	Meeting 14 10 2020 – Agenda	Ares(2020)6522634
46	Meeting 14 10 2020 – Minutes	Ares(2020)6522697
47	Meeting 16 10 2020 – Agenda	Ares(2020)6522756
48	Meeting 16 10 2020 – Minutes	Ares(2020)6522806
49	Meeting 23 10 2020 – Agenda	Ares(2020)6522867
50	Meeting 23 10 2020 – Minutes	Ares(2020)6522914
51	Meeting 30 10 2020 – Agenda	Ares(2020)6546874
52	Meeting 30 10 2020 – Minutes	Ares(2020)6546963
53	Meeting 06 11 2020 – Agenda	Ares(2020)6549469
54	Meeting 06 11 2020 – Minutes	Ares(2020)6822297
55	Meeting 09 11 2020 – Agenda	Ares(2020)6700434
56	Meeting 09 11 2020 – Minutes	Ares(2020)6822297
57	Meeting 11 11 2020 – Agenda	Ares(2020)6700526
58	Meeting 11 11 2020 – Minutes	Ares(2020)6822297
59	Meeting 13 11 2020 – Agenda	Ares(2020)6685168
60	Meeting 13 11 2020 – Minutes	Ares(2020)6910555
61	Meeting 18 11 2020 – Agenda	Ares(2020)6858996
62	Meeting 18 11 2020 – Minutes	Ares(2020)7145086
63	Meeting 20 11 2020 – Agenda	Ares(2020)6958024
64	Meeting 20 11 2020 – Minutes	Ares(2020)7145086
65	Meeting 24 11 2020 – Agenda	Ares(2020)7057966
66	Meeting 24 11 2020 – Minutes	Ares(2020)7145086
67	Meeting 27 11 2020 – Agenda	Ares(2020)7145198
68	Meeting 27 11 2020 – Minutes	Ares(2020)7726204
69	Meeting 04 12 2020 – Agenda	Ares(2020)7726247

70	Meeting 04 12 2020 – Minutes	Ares(2021)1559931
71	Meeting 11 12 2020 – Agenda	Ares(2020)7726309
72	Meeting 11 12 2020 – Minutes	Ares(2021)1559931
73	Meeting 17 12 2020 – Agenda	Ares(2020)7820538
74	Meeting 17 12 2020 – Minutes	Ares(2021)72615
75	Meeting 18 12 2020 – Agenda	Ares(2020)7726350
76	Meeting 18 12 2020 – Minutes	Ares(2021)72615
77	Meeting 23 12 2020 – Agenda	Ares(2020)7896014
78	Meeting 23 12 2020 – Minutes	Ares(2021)538728
79	Meeting 28 12 2020 – Agenda	Ares(2021)637985
80	Meeting 28 12 2020 – Minutes	Ares(2021)538837
81	Meeting 31 12 2020 – Agenda	Ares(2021)638026
82	Meeting 31 12 2020 – Minutes	Ares(2021)538954
83	Meeting 04 01 2021– Agenda	Ares(2021)72771
84	Meeting 04 01 2021 – Minutes	Ares(2021)539009
85	Meeting 06 01 2021– Agenda	Ares(2021)72889
86	Meeting 06 01 2021 – Minutes	Ares(2021)539009
87	Meeting 08 01 2021– Agenda	Ares(2021)638066
88	Meeting 08 01 2021 – Minutes	Ares(2021)539076
89	Meeting 11 01 2021– Agenda	Ares(2021)638103
90	Meeting 11 01 2021 – Minutes	Ares(2021)539076
91	Scientific Presentation by AstraZeneca Representatives - 5 August 2020 - Report and Presentation	Ares(2021)1080979
92	Scientific Update by Sanofi Pasteur Representatives -17 December 2020 - Report and Presentation	Ares(2021)1080388
93	Scientific Update by CureVac Representatives, 17 November 2020 - Pre-Clinical and Clinical Development Data Update - Report and Presentation	Ares(2021)1080162
94	Scientific Update by CureVac Representatives, 3 November 2020 - Report and Presentation	Ares(2021)1080039
95	Scientific Presentation by ReiThera Representatives, 8 October 2020 - Report and Presentation	Ares(2021)1079851
96	Follow-up Discussion to the Scientific Presentation by CureVac Representatives, 7 October 2020	Ares(2021)1079748
97	Scientific Presentation by CureVac Representatives, 28 September 2020 - Report and Presentation	Ares(2021)1079689
98	Scientific Presentation by Sanofi-GSK Representatives, 9 September 2020 - Report and Presentation	Ares(2021)1079599
99	Scientific Presentation by Johnson & Johnson Representatives, 4 September 2020 - Report and Presentation	Ares(2021)1079177
100	Scientific Presentation by CureVac Representatives, 28 August 2020 - Report and Presentation	Ares(2021)1078991
101	Scientific Presentation by Novavax Representatives, 11 August 2020 - Report and Presentation	Ares(2021)1078824
102	Scientific Presentation by BioNTech/ Pfizer Representatives - 7 August 2020 - Report	Ares(2021)1078029
103	Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 - Report of the meeting	Ares(2021)1077783
104	Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 - Scientific considerations regarding the adenovirus vectored vaccines against SARS-COV-2 - Opinion of the Spanish Scientific Committee	Ares(2021)1077720
105	Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 - Scientific considerations regarding the adenovirus vectored vaccines against SARS-COV-2 - Opinion of the French Scientific Committee	Ares(2021)1077657
106	Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 - Scientific considerations regarding the adenovirus vectored vaccines against SARS-COV-2 - Opinion of the Dutch Scientific Committee	Ares(2021)1077597
107	European Commission’s advisory panel on COVID-19, Invitation letter and report – videoconference 20/07/2020	Ares(2021)1077274
108	Scientific Update by AstraZeneca Representatives - Safety and efficacy - 15 December 2020	Ares(2021)1080275
109	Scientific meeting with Moderna, 15 July 2020	Ares(2021)1076405
110	Overview of contacts with companies on COVID-19 vaccine presented to the Steering Board, 26.02.2021	Ares(2021)1571176
111	Overview of contacts with companies on COVID-19 vaccine presented to the Steering Board, 03.11.2020	Ares(2021)1571156
112	Overview of contacts with companies on COVID-19 vaccine presented to the Steering Board, 30.07.2020	Ares(2021)1571126
113	Overview of contacts with companies on COVID-19 vaccine presented to the Steering Board, 14.07.2020	Ares(2021)1571111
	ASTRA ZENECA	
114	Contract 27-08-2020	Ares(2020)4849918
115	1. Draft APA negotiated between AstraZeneca and the Evaluation Committee on 13-08-20	Ares(2020)7907431
116	2. Draft APA negotiated between AstraZeneca and EvaluationCommittee on 13-08-20 2	Ares(2020)7908740
117	1.AstraZeneca COVID-19 Vaccine Update on developments sent to the European Commission	Ares(2020)7909560
118	2. AW Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 1 (DE)	Ares(2021)659748
119	3. AW Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 2 (DE)	Ares(2020)7910195
120	4. Follow up - AZ EC exploratory meeting	Ares(2020)7910870
121	5. Re URGENT - info about suspension of clinical trials for COVID-19 vaccine	Ares(2021)30264
122	6. RE Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 3 (FR)	Ares(2021)30582

123	7. RE Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 4 (FR)	Ares(2021)30690
124	8. TR Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 5 (FR)	Ares(2021)30943
125	9. WG Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 6 (DE)	Ares(2021)31153
126	Call for tenders SANTE/2020/C3/037 for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States	Ares(2021)312429
127	RE: CALL FOR TENDERS SANTE/2020/C3/037 – OFFER	Ares(2021)340821
128	SANTE/2020/C3/037 - Notification Letter : Call for tenders for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States	Ares(2020)4344395
129	Notification letter: SANTE/2020/C3/037: Development, production, priority-purchasing options and supply of COVID-19	Ares(2021)340783
130	SARS CoV-2 Vaccine (AZD1222) Progress Report 19 January 2021	Ares(2021)496499
131	MHRA Public Assessment Report AZ Covid-19 Vaccine	Ares(2021)282661
132	RE: Follow up from yesterday meeting	Ares(2021)930498
133	Commission IR 2021/111 of 29 Jan 2021	Ares(2021)852331
134	APA AstraZeneca – 2nd instalment payment – second request for full report	Ares(2020)7686288
135	APA AstraZeneca – 2nd instalment payment request – Response letter	Ares(2021)732342
136	follow-up questionnaire - sent to Astra Zeneca	Ares(2020)2765988
137	skype meeting with Astra Zeneca - 14/05/2020 - vaccines	Ares(2020)2765906
	Pfizer & BioNTech	
138	Contract	Ares(2021)256798
139	1. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee 06-11-2020	Ares(2021)99788
140	2. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical) 07-11-2020	Ares(2021)100050
141	3. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical)09-11-2020 2	Ares(2021)100183
142	4. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical)09-11-2020 3	Ares(2021)100479
143	5. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical) 09-11-2020	Ares(2021)100626
144	6. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee 14-10-2020	Ares(2021)100720
145	7. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical) 19-10-2020	Ares(2021)100871
146	1. Expression of interest BioNTech&Pfizer to DE	Ares(2021)36267
147	2. BioNTech&Pfizer Expression of Interest summary by DE	Ares(2021)36708
148	3. Reply to BioNTech&Pfizer EoI by the Commission	Ares(2021)40997
149	4. BioNTech&Pfizer EoI to the Commission	Ares(2021)41184
150	5. BioNTech&Pfizer COVID19 Vaccine information (BNTPF)	Ares(2021)42169
151	6. Draft Indemnification clause BioNTech&Pfizer sent to DE	Ares(2021)42400
152	7. Draft TermSheet BioNTech&Pfizer Vaccines from DE	Ares(2021)42905
153	8. Pfizer&BioNTech Indemnification Clause Discussion	Ares(2021)43131
154	9. Draft TermSheet BioNTech&Pfizer Vaccines comments JNT (DE) call 23 07 2020	Ares(2021)45314
155	10. Draft TermSheet BioNTech&Pfizer Vaccines comments JNT (DE) call 24 07 2020	Ares(2021)46121
156	11. Draft TermSheet BioNTech&Pfizer Vaccines comments JNT call 30 07 2020	Ares(2021)46581
157	12. Follow up exploratory talks BioNTech call 12 06 2020	Ares(2021)47109
158	13. Follow up exploratory talks Pfizer call 08 06 2020	Ares(2021)47809
159	14. BioNTech ppt exploratory talks 12 06 2020	Ares(2021)48086
160	Question 1 in scope of Invitation to tender for procedure SANTE 2020/C3/043 (BN Pfizer)	Ares(2020)5095191
161	Answer to question 1 in scope of Invitation to tender for procedure SANTE 2020/C3/043 (BN Pfizer)	Ares(2020)5095180
162	Invitation to tender	Ares(2021)312344
163	Tender submission (in 3 emails)	Ares(2021)340523
164	CALL FOR TENDERS SANTE/2020/C3/043 - OFFER - email 1 of 3	Ares(2021)340523
165	CALL FOR TENDERS SANTE/2020/C3/043 - OFFER - email 2 of 3	Ares(2021)340593
166	CALL FOR TENDERS SANTE/2020/C3/043 - OFFER - email 3 of 3	Ares(2021)340474
167	Notification Letter	Ares(2020)6801133
168	Notification Letter sent to Pfizer/BNT informing of the outcome of the award procedure	Ares(2021)433162
169	Invitation to tender	Ares(2021)312233
170	Tender submission	Ares(2021)471003
171	Notification Letter	Ares(2021)1090683
172	Notification Letter sent to Pfizer/BNT informing of the outcome of the award procedure	Ares(2021)1092982
173	Advance purchase agreement signed by Pfizer/BNT (in 2 emails)	Ares(2021)1366751 Ares(2021)1366893
174	Contract 17-02-2021	Ares(2021)1601544
	Janssen Pharmaceutica	
175	Contract 21-10-2020	Ares(2020)5806059
176	1. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 04-09-2020	Ares(2021)74830
177	2. Draft APA negotiated between J&J and the Evaluation Committee 15-09-2020	Ares(2021)106692
178	3. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 18-09-2020	Ares(2021)75337
179	4. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 25-09-2020	Ares(2021)76546
180	5. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 28-09-2020	Ares(2021)76834
181	6. Draft APA negotiated between J&J and the Evaluation Committee 01-10-2020	Ares(2021)106925
182	7. Draft APA negotiated between J&J and the Evaluation Committee (technical) 02-10-2020	Ares(2021)107085
183	8. Draft APA negotiated between J&J and the Evaluation Committee (technical) 06-10-2020	Ares(2021)107537
184	1. Janssen_J&J Expression of Intrest to the EC re COVID-19 vaccine	Ares(2021)132146
185	3. Janssen_J&J response to the questionnaire	Ares(2021)132330
186	4. Janssen_J&J COVID-19 vaccine proposal to the EC (1)- call 6-05-2020	Ares(2021)132368

187	5. Janssen_J&J COVID-19 vaccine proposal to the EC (2)	Ares(2021)132455
188	6. Jansen_J&J COVID-19 vaccine proposal to the EC (3) - call 10-06-2020	Ares(2021)132976
189	7. Jansen_J&J COVID-19 vaccine proposal to the EC (4)- follow up call 10-06-2020	Ares(2021)133168
190	8. Draft term sheet discussed with Jansen_J&J at the Joint Negotiation Team during the exploratory talks on 11-06-2020	Ares(2021)133223
191	9. Draft term sheet discussed with Jansen_J&J at the Joint Negotiation Team during the exploratory talks on 17-06-2020	Ares(2021)133506
192	10. Jansen_J&J COVID-19 vaccine proposal to the EC and EU4 (5)	Ares(2021)133741
193	11. Draft term sheet discussed with Jansen_J&J at the Joint Negotiation Team during the exploratory talks on 10-08-2020	Ares(2021)133989
194	Call for tenders SANTE/2020/C3/047 for the development, production, priority-purchasing options and supply of COVID-19	Ares(2021)312329
195	CALL FOR TENDERS SANTE/2020/C3/047 - OFFER	Ares(2021)340694
196	SANTE/2020/C3/047 - Notification Letter : Call for tenders for the development, production, priority-purchasing options and	Ares(2020)5389787
197	Notification letter: SANTE/2020/C3/047: Development, production, priority-purchasing options and supply of COVID-19 Va	Ares(2021)340726
198	Follow-up questionnaire - sent to Johnson & Johnson / Janssen	Ares(2020)2522007
199	skype meeting with Johnson & Johnson / Janssen - vaccine - 06/05/2020	Ares(2020)2521465
200	Report from the TC with J&J on COVID 19 Vaccine	Ares(2020)1972413
201	Summary: J&J TC on COVID 19 Vaccine	Ares(2020)1970797
202	[Re] Summary: J&J TC on COVID 19 Vaccine	Ares(2020)1970819
203	BTO: Johnson & Johnson meeting with Martin Seychell, 11 March 2020	Ares(2020)2095729
204	RE: Study: Johnson and Johnson vaccine successfully prevents COVID-19 infections in monkeys	Ares(2020)4104461
205	J&J accelerates COVID-19 vaccine development (Phase 1/2a Clinical Trials in Belgium starting July 2020) and supports global collaborations for equitable access	Ares(2020)3237436
206	J&J Joins Industry Partners to Launch the \$1 Billion AMR Action Fund	Ares(2020)3695189
207	Johnson & Johnson announces a Lead Vaccine Candidate for COVID-19	Ares(2020)2162139
208	[Re] Johnson & Johnson announces a Lead Vaccine Candidate for COVID-19	Ares(2020)2162181
209	RE: J&J Announces a Lead Vaccine Candidate for COVID-19	Ares(2020)1947633
210	Johnson & Johnson COVID-19 vaccine development update: launch of Phase 3 clinical trials	Ares(2020)5010997
211	Johnson & Johnson COVID-19 treatment development update	Ares(2020)4299316

Moderna

212	Contract 04-12-2020	Ares(2021)256592
213	1. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 29-06-2020	Ares(2021)338082
214	2. Draft APA negotiated between Moderna and the Evaluation Committee on 04.11.2020- 4 pm	Ares(2021)338541
215	3. Draft APA negotiated between Moderna and the Evaluation Committee (technical) 12-11-2020	Ares(2021)339263
216	4. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 18-11-2020	Ares(2021)339518
217	5. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 18-11-2020 2	Ares(2021)340423
218	6. Draft APA negotiated between Moderna and the Evaluation Committee on 19-11-2020	Ares(2021)340719
219	7. Draft APA negotiated between Moderna and the Evaluation Committee on 19-11-2020 2	Ares(2021)341318
220	8. Draft APA negotiated between Moderna and the Evaluation Committee (model annex) on 19-11-2020	Ares(2021)341559
221	9. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 21-11-2020	Ares(2021)341766
222	10. Draft APA negotiated between Moderna and the Evaluation Committee (technical) 22-11-2020 2	Ares(2021)341980
223	11. Draft APA negotiated between Moderna and the Evaluation Committee (technical) 22-11-2020	Ares(2021)342118
224	12. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 24-11-2020 1	Ares(2021)343169
225	13. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 24-11-2020 2	Ares(2021)343317
226	14. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 24-11-2020 3	Ares(2021)343486
227	Question 1 in scope of Invitation to tender for procedure SANTE 2020/C3/054 (Moderna)	Ares(2020)5069122
228	Answer to question 1 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)	Ares(2020)5069081
229	Question 2 in scope of Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)	Ares(2020)5069065
230	Answer to question 2 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)	Ares(2020)5069108
231	Complement Answer to question 2 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)	Ares(2020)5095249
232	Question 3 in scope of Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)	Ares(2020)5095385
233	Answer to question 3 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)	Ares(2020)5095409
234	Call for tenders SANTE/2020/C3/054 for the development, production, priority-purchasing options and supply of COVID-19	Ares(2021)312291
235	CALL FOR TENDERS SANTE/2020/C3/054 – OFFER	Ares(2021)340662
236	SANTE/2020/C3/054 - Notification Letter : Call for tenders for the development, production, priority-purchasing options and	Ares(2020)7207031
237	Notification letter: SANTE/2020/C3/054: Development, production, priority-purchasing options and supply of COVID-19 Va	Ares(2021)340640
238	5. Moderna info on EMA submission timeline for mRNA1273 02-08-2020	Ares(2021)435827
239	8. Moderna draft Term Sheet discussed with the JNT (i&l clauses) 20-08-2020	Ares(2021)434268
240	7. Moderna draft Term Sheet discussed with the JNT (i clause) 14-08-2020	Ares(2021)434180
241	6. Moderna draft Term Sheet discussed with the JNT 11-08-2020	Ares(2021)434093
242	4. Moderna draft Term Sheet discussed with the JNT (i clause) 30-07-2020	Ares(2021)433869
243	3. Reply to Moderna proposal by the Commission (SB feedback) 22-07- 2020	Ares(2021)433707
244	2. Moderna revised proposal 10-07-2020.docx (153 KB)	Ares(2021)430505
245	1. Moderna Expression of Interest to the EC re COVID-19 vaccine 29-06-2020	Ares(2021)430233
246	Invitation to tender SANTE/2021/C3/010	Ares(2021)893598
247	Tender submission	Ares(2021)1012684
248	request for clarifications and missing documents (call or tenders SANTE/2021/C3/010)	Ares(2021)1153333
249	clarifications and missing documents (call or tenders SANTE/2021/C3/010)	Ares(2021)1255168
250	RE: Meeting of the Evaluation Committee with Moderna- 12.02.2021 at 16.00	Ares(2021)1638774
251	RE: Meeting of the Evaluation Committee with Moderna- today (15/02) at 21:00	Ares(2021)1639274
252	RE: SANTE/2021/C3/010- Meeting of the Evaluation Committee with Moderna - 11.02.2021	Ares(2021)1639254
253	Notification Letter	Ares(2021)1336686
254	Notification Letter sent to Moderna informing of the outcome of the award procedure	Ares(2021)1342678
255	Meeting of the Evaluation Committee with Moderna- 12.02.2021 at 16.00	Ares(2021)1638506

256	Moderna questions on the contract signature-19.02.2021	Ares(2021)1638716
257	Contract 01-03-2021	Ares(2021)1601566
CureVac		
260	Contract 30-11-2020	Ares(2021)256728
261	1. Draft APA negotiated between CureVac and the Evaluation Committee on 18-09-2020	Ares(2021)274633
262	2. Draft APA negotiated between CureVac and the Evaluation Committee (technical) on 25-09-202	Ares(2021)288612
263	3. PreREADS CureVac Scientific presentation to Member States on 28-09-2020	Ares(2021)275043
264	4. CureVac Scientific presentation to Member States on 28-09-2020	Ares(2021)275521
265	5. CureVac Scientific presentation to Member States on 3-11-2020	Ares(2021)274831
266	6. Draft APA negotiated between CureVac and the Evaluation Committee on 12-11-2020	Ares(2021)275777
267	7. Draft APA negotiated between CureVac and the Evaluation Committee (technical) on 24-11-2020	Ares(2021)276026
268	1. CureVac Expression of Interest to the EC re COVID-19 vaccine- call 07-05-2020	Ares(2021)302052
269	2. CureVac Expression of Interest to the EC re COVID-19 vaccine - feedback EIB	Ares(2021)302551
270	3. CureVac - response to the questionnaire	Ares(2021)746001
271	4. CureVac Proposal to the EC re COVID-19 vaccine	Ares(2021)304292
272	5. CureVac Proposal to the EC re COVID-19 vaccine- follow up	Ares(2021)304832
273	6. CureVac draft Term Sheet discussed with the Joint Negotiation Team (first draft)16-06-2020	Ares(2021)305213
274	7. CureVac draft Term Sheet Joint Negotiation Team comments (FR) 08-07-2020	Ares(2021)305545
275	8. CureVac draft Term Sheet Joint Negotiation Team comments (EC) 08-07-2020 2	Ares(2021)306003
276	9. CureVac draft Term Sheet discussed with the Joint Negotiation Team 28-07-2020	Ares(2021)310065
277	10. CureVac draft Term Sheet discussed with the Joint Negotiation Team on 11-08-2020	Ares(2021)311112
278	11. CureVac COVID-19 vaccine update and current data from clinical trials 17-08-2020	Ares(2021)311541
279	12. CureVac draft Term Sheet discussed with the Joint Negotiation Team (L&I clause) 17-08-2020	Ares(2021)311799
280	13. CureVac draft Term Sheet discussed with the Joint Negotiation Team 18-08-2020	Ares(2021)312173
281	14. CureVac draft Term Sheet discussed with the Joint Negotiation Team (L&I clause pre-final) 19-08-2020	Ares(2021)312280
282	15. CureVac draft Term Sheet discussed with the Joint Negotiation Team (L&I clause final) 19-08-2020	Ares(2021)312597
283	16. CureVac investigational brochure (IB) for COVID-19 vaccine	Ares(2021)312869
284	Question 1 in scope of Invitation to tender for procedure SANTE 2020/C3/049 (Curevac)	Ares(2020)5095417
285	Question 2 in scope of Invitation to tender for procedure SANTE 2020/C3/049 (Curevac)	Ares(2020)5095266
286	Question 3 in scope of Invitation to tender for procedure SANTE 2020/C3/049 (Curevac)	Ares(2020)5097658
287	Answer to question 1 & 3 - Invitation to tender for procedure SANTE/2020/C3/054 (Curevac)	Ares(2020)5095255
288	Answer to question 2 - Invitation to tender for procedure SANTE/2020/C3/054 (Curevac)	Ares(2020)5095206
289	Call for tenders SANTE/2020/C3/049 for the development, production, priority-purchasing options and supply of COVID-19	Ares(2021)312310
290	Tender submission (see 8 below entries - submission in 8 emails)	Ares(2021)399673
291	Call for tenders SANTE/2020/C3/049 - Offer (1)	Ares(2021)399673
292	Call for tenders SANTE/2020/C3/049 - Offer (2)	Ares(2021)402256
293	Call for tenders SANTE/2020/C3/049 - Offer (3)	Ares(2021)402334
294	Call for tenders SANTE/2020/C3/049 - Offer (4)	Ares(2021)402575
295	Call for tenders SANTE/2020/C3/049 - Offer (5)	Ares(2021)402769
296	Call for tenders SANTE/2020/C3/049 - Offer (6)	Ares(2021)403272
297	Call for tenders SANTE/2020/C3/049 - Offer (7)	Ares(2021)403541
298	Call for tenders SANTE/2020/C3/049 - Offer (8)	Ares(2021)403817
299	SANTE/2020/C3/049 - Notification Letter : Call for tenders for the development, production, priority-purchasing options and supply of COVID-19 Vaccine	Ares(2020)6962203
300	Notification letter: SANTE/2020/C3/049: Development, production, priority-purchasing options and supply of COVID-19 Vaccine	Ares(2021)340610
301	Follow-up questionnaire - sent to CureVac	Ares(2020)2524003
302	skype meeting with CureVac - vaccine - 07/05/2020	Ares(2020)2523066
Sanofi – GSK		
303	Contract 18-09-2020	Ares(2020)5034184
304	Call for tenders SANTE/2020/C3/042 for the development, production, priority-purchasing options and supply of COVID-19 Vaccine	Ares(2021)312411
305	CALL FOR TENDERS SANTE/2020/C3/042 – OFFER	Ares(2020)4206796
306	SANTE/2020/C3/042 - Notification Letter : Call for tenders for the development, production, priority-purchasing options and supply of COVID-19 Vaccine	Ares(2020)4819456
307	Notification letter: SANTE/2020/C3/042: Development, production, priority-purchasing options and supply of COVID-19 Vaccine	Ares(2021)340742
308	1. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-20	Ares(2021)631289
309	2. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-2020 App	Ares(2021)631900
310	3. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 03-09-20	Ares(2021)632544
311	4. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 04-09-20	Ares(2021)639004
312	5. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 05-09-20	Ares(2021)660367
313	6. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 10-09-20	Ares(2021)660645
314	7. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20	Ares(2021)661481
315	8. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20 2	Ares(2021)661630
316	9. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20 3	Ares(2021)666517
317	10. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 14-09-20	Ares(2021)666695
318	11. Final APA sent to Sanofi&GSK for signature 16-09-20	Ares(2021)666857
319	12. Scan of a signed version of the APA sent to Sanofi&GSK 25-09-20	Ares(2021)667173
320	13. Sanofi-GSK COVID19 vaccine - Progress report 26-10-20	Ares(2021)740978
321	Sanofi&GSK proposed options on post approval studies 08-09-20	Ares(2021)741313
322	Sanofi&GSK Scientific technical presentation Sanofi-GSK 09-09-20	Ares(2021)745642
323	Summary of the meeting with Sanofi, 26 October, 12:00 – 12:45 pm, via WebEx	Ares(2021)537955
324	1. Sanofi response to the questionnaire 19-05-20	Ares(2021)705386
325	2. GSK response to the questionnaire 21-05-20	Ares(2021)733401
326	3. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 12-06-20	Ares(2021)733690
327	4. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 22-06-20	Ares(2021)734569

328	5. Sanofi&GSK pre reads exploratory talks 24-06-20	Ares(2021)735100
329	6. Sanofi&GSK presentation exploratory talks 25-06-20	Ares(2021)737035
330	7. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 29-06-20	Ares(2021)738210
331	8. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 10-07-20	Ares(2021)738991
332	9. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 22-07-20	Ares(2021)739448
333	10. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 29-07-20	Ares(2021)739764
334	Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19	Ares(2020)2074101
335	Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19	Ares(2020)2040853
336	meeting with SANOFI on APIS on 2.04 - bto	Ares(2020)2270849
337	follow-up questionnaire - sent to GSK	Ares(2020)2566039
338	skype meeting with GSK - 12/05/2020 - vaccines	Ares(2020)2565985

NOVAVAX

339	Novavax exploratory talks outcome 11.12.2020	Ares(2021)1743132
340	Novavax exploratory talks with JNT Indemnity Liability Comments 5.11.2020	Ares(2021)1764702
341	Novavax exploratory talks with JNT 6.12.2020	Ares(2021)1764761
342	Novavax exploratory talks with JNT 9.12.2020	Ares(2021)1764880
343	Novavax exploratory talks with JNT 25.08.2020	Ares(2021)1765007
344	Novavax exploratory talks with JNT 26.08.2020	Ares(2021)1765220
345	Novavax exploratory talks with JNT Idemnification 19.09.2020	Ares(2021)1765346
346	Invitation to tender SANTE/2020/C3/087	Ares(2021)312276
347	Q1 : RE: Call for tenders SANTE/2020/C3/087 for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States	Ares(2020)8014575
348	Answer to Q1 (part 1)	Ares(2020)8014640
349	Answer to Q1 (part 2) : RE: SANTE/2020/C3/087 - question on deadline	Ares(2020)8014730
350	Tender submission	Ares(2021)1559399
351	Draft APA based on your tender	Ares(2021)492534
352	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 1)	Ares(2021)936217
353	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (answer 1)	Ares(2021)471056
354	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 2)	Ares(2021)938164
355	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (answer 2)	Ares(2021)471028
356	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 3)	Ares(2021)935939
357	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (answer 3)	Ares(2021)471078
358	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 1) - follow up	Ares(2021)938280
359	RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 1) - follow up - answer	Ares(2021)935801
360	RE: CALL FOR TENDERS SANTE/2020/C3/087 - New Subcontractors	Ares(2021)1554765
361	Novavax / EU Commission Draft APA 03/02/2021	Ares(2021)1742633
362	Novavax / EU Commission Draft APA 14/11/2020	Ares(2021)1742497
363	Novavax Investigator Brochure 06/02/2021	Ares(2021)1742746
364	RE: Meeting of the Evaluation Committee with Novavax- Thursday 04.03.21 at 4.30 pm	Ares(2021)1742899
365	RE: Meeting of the Evaluation Committee with Novavax- Thursday 04.03.21 at 4.30 pm_2	Ares(2021)1742977